Prof. Andrea Tüttenberg, MD
Andrea Tüttenberg is managing director of ActiTrexx GmbH and acts as Chief Executive Officer as well as Chief Medical Officer at ActiTrexx. She is responsible for strategic direction and overall clinical development, as well as medical guidance of Actileucel development.
Andrea Tüttenberg is assistant professor within the Department of Dermatology, Johannes Gutenberg-University where she gained extensive clinical experience as a senior physician and head of the Department of Dermatological Ultra-Sound. She has expert knowledge in basic and translational science, with a focus on the modulation of immune responses in human immune-related diseases. Prof. Tüttenberg developed the first clinical cellular vaccination trials for malignant melanoma under GMP conditions. She has received many awards since the start of her career, including the GO-Bio Award from the German Federal Ministry of Education and Research, the Dermato-Oncology Award from the Society of Dermatological Research and the Boehringer Ingelheim Award. Alongside her academic career, Andrea Tüttenberg is on the editorial board for several journals and also acts as a reviewer for a number of journals, including Journal of Immunology. In addition, she is on the Selection Committee for the Scholarship of the German National Academic Foundation.